ZCI
VRTX icon

Zevenbergen Capital Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Zevenbergen Capital Investments’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-240,600
Closed -$17.9M – 76
2013
Q4 		$17.9M Sell
240,600
-21,600
-8% -$1.5M 0.62% 45
2013
Q3 		$19.9M Sell
262,200
-6,550
-2% -$521K 0.67% 40
2013
Q2 		$21.5M Buy
+268,750
New +$19.8M 0.87% 38

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Zevenbergen Capital Investments's VRTX Position: Q1 2014 in Review

Zevenbergen Capital Investments sold out of Vertex Pharmaceuticals (VRTX) in Q1 2014, closing a stake of 240,600 shares — an estimated $17.9M sold.

Zevenbergen Capital Investments first reported a position in VRTX in Q2 2013 and held it in 3 quarters. The position peaked at $21.5M in Q2 2013. 395 funds tracked by Wall St. Rank hold VRTX as of Q1 2014.

  • Zevenbergen Capital Investments reported no remaining Vertex Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Zevenbergen Capital Investments sold 240,600 Vertex Pharmaceuticals shares in Q1 2014, an estimated $17.9M.
  • Zevenbergen Capital Investments first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Zevenbergen Capital Investments's Vertex Pharmaceuticals position peaked at $21.5M in Q2 2013.
  • 395 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2014.

Based on Zevenbergen Capital Investments's 13F filing for Q1 2014, filed 12 May 2014.